IL100905A - Pharmaceuticals containing rapamycin for the treatment of pneumonia - Google Patents
Pharmaceuticals containing rapamycin for the treatment of pneumoniaInfo
- Publication number
- IL100905A IL100905A IL10090592A IL10090592A IL100905A IL 100905 A IL100905 A IL 100905A IL 10090592 A IL10090592 A IL 10090592A IL 10090592 A IL10090592 A IL 10090592A IL 100905 A IL100905 A IL 100905A
- Authority
- IL
- Israel
- Prior art keywords
- rapamycin
- pharmaceutical composition
- mammal
- composition according
- pulmonary inflammation
- Prior art date
Links
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title claims abstract description 19
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title claims abstract description 19
- 229960002930 sirolimus Drugs 0.000 title claims abstract description 19
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 10
- 208000006673 asthma Diseases 0.000 claims abstract description 10
- 241000124008 Mammalia Species 0.000 claims abstract description 7
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims abstract description 4
- 206010014561 Emphysema Diseases 0.000 claims abstract description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims abstract description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims abstract description 4
- 206010006451 bronchitis Diseases 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 210000004969 inflammatory cell Anatomy 0.000 description 7
- 230000004941 influx Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187391 Streptomyces hygroscopicus Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Liquid Crystal Substances (AREA)
- External Artificial Organs (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/659,782 US5080899A (en) | 1991-02-22 | 1991-02-22 | Method of treating pulmonary inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL100905A0 IL100905A0 (en) | 1992-11-15 |
| IL100905A true IL100905A (en) | 1995-11-27 |
Family
ID=24646823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10090592A IL100905A (en) | 1991-02-22 | 1992-02-10 | Pharmaceuticals containing rapamycin for the treatment of pneumonia |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5080899A (es) |
| EP (1) | EP0573584B1 (es) |
| JP (1) | JP2673168B2 (es) |
| KR (1) | KR100201516B1 (es) |
| AT (1) | ATE183647T1 (es) |
| AU (1) | AU662735B2 (es) |
| CA (1) | CA2103571C (es) |
| DE (1) | DE69229858T2 (es) |
| DK (1) | DK0573584T3 (es) |
| ES (1) | ES2135404T3 (es) |
| GR (1) | GR3031681T3 (es) |
| HU (1) | HUT70146A (es) |
| IE (1) | IE920554A1 (es) |
| IL (1) | IL100905A (es) |
| LV (1) | LV12400B (es) |
| NZ (1) | NZ241672A (es) |
| PT (1) | PT100144B (es) |
| SG (1) | SG52403A1 (es) |
| WO (1) | WO1992014476A1 (es) |
| ZA (1) | ZA921211B (es) |
Families Citing this family (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| US5221670A (en) * | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
| US5378696A (en) * | 1990-09-19 | 1995-01-03 | American Home Products Corporation | Rapamycin esters |
| US5358944A (en) * | 1990-09-19 | 1994-10-25 | American Home Products Corporation | Rapamycin esters for treating transplantation rejection |
| US5321009A (en) * | 1991-04-03 | 1994-06-14 | American Home Products Corporation | Method of treating diabetes |
| US5194447A (en) * | 1992-02-18 | 1993-03-16 | American Home Products Corporation | Sulfonylcarbamates of rapamycin |
| US5286731A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
| US5286730A (en) * | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
| US5164399A (en) * | 1991-11-18 | 1992-11-17 | American Home Products Corporation | Rapamycin pyrazoles |
| US5516781A (en) * | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
| US5262424A (en) * | 1992-02-18 | 1993-11-16 | American Home Products Corporation | Composition of sulfonylcarbamates of rapamycin and method of treating diseases requiring immunosuppression therewith |
| US5177203A (en) * | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
| ATE138807T1 (de) | 1992-03-27 | 1996-06-15 | American Home Prod | 29-demethoxyrapamycin zur induktion der immunosuppression |
| US5288711A (en) * | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
| US5256790A (en) * | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
| CA2106034A1 (en) * | 1992-09-24 | 1994-03-25 | Ralph J. Russo | 21-norrapamycin |
| US5480989A (en) * | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5489680A (en) * | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
| US5302584A (en) * | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
| US5480988A (en) * | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
| US5434260A (en) * | 1992-10-13 | 1995-07-18 | American Home Products Corporation | Carbamates of rapamycin |
| US5262423A (en) * | 1992-10-29 | 1993-11-16 | American Home Products Corporation | Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents |
| US5260300A (en) * | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
| US5349060A (en) * | 1993-01-07 | 1994-09-20 | American Home Products Corporation | Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents |
| US5252579A (en) * | 1993-02-16 | 1993-10-12 | American Home Products Corporation | Macrocyclic immunomodulators |
| US5504091A (en) * | 1993-04-23 | 1996-04-02 | American Home Products Corporation | Biotin esters of rapamycin |
| AU686629B2 (en) | 1993-04-23 | 1998-02-12 | Wyeth | Rapamycin Conjugates and Antibodies |
| US7279561B1 (en) | 1993-04-23 | 2007-10-09 | Wyeth | Anti-rapamycin monoclonal antibodies |
| US5387680A (en) * | 1993-08-10 | 1995-02-07 | American Home Products Corporation | C-22 ring stabilized rapamycin derivatives |
| US5616588A (en) * | 1993-09-30 | 1997-04-01 | American Home Products Corporation | Rapamycin formulation for IV injection |
| US5536729A (en) * | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
| IL111004A (en) * | 1993-09-30 | 1998-06-15 | American Home Prod | Oral formulations of rapamycin |
| US5516770A (en) * | 1993-09-30 | 1996-05-14 | American Home Products Corporation | Rapamycin formulation for IV injection |
| US5373014A (en) * | 1993-10-08 | 1994-12-13 | American Home Products Corporation | Rapamycin oximes |
| US5378836A (en) * | 1993-10-08 | 1995-01-03 | American Home Products Corporation | Rapamycin oximes and hydrazones |
| US5391730A (en) * | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
| US5385910A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Gem-distributed esters of rapamycin |
| US5385908A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
| US5385909A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Heterocyclic esters of rapamycin |
| US5389639A (en) * | 1993-12-29 | 1995-02-14 | American Home Products Company | Amino alkanoic esters of rapamycin |
| US5525610A (en) * | 1994-03-31 | 1996-06-11 | American Home Products Corporation | 42-Epi-rapamycin and pharmaceutical compositions thereof |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| US5463048A (en) * | 1994-06-14 | 1995-10-31 | American Home Products Corporation | Rapamycin amidino carbamates |
| US5491231A (en) * | 1994-11-28 | 1996-02-13 | American Home Products Corporation | Hindered N-oxide esters of rapamycin |
| US5563145A (en) * | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
| US5561138A (en) | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
| US5496832A (en) * | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
| US5780462A (en) * | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
| US5922730A (en) * | 1996-09-09 | 1999-07-13 | American Home Products Corporation | Alkylated rapamycin derivatives |
| IT1289815B1 (it) * | 1996-12-30 | 1998-10-16 | Sorin Biomedica Cardio Spa | Stent per angioplastica e relativo procedimento di produzione |
| PT1024814E (pt) * | 1997-10-22 | 2007-11-29 | Mayo Foundation | Utilização de agentes antifúngicos para o tratamento tópico de mucosite induzida por fungo |
| US6015809A (en) * | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
| US6331547B1 (en) | 1999-08-18 | 2001-12-18 | American Home Products Corporation | Water soluble SDZ RAD esters |
| US6670355B2 (en) * | 2000-06-16 | 2003-12-30 | Wyeth | Method of treating cardiovascular disease |
| ATE411321T1 (de) | 2000-09-19 | 2008-10-15 | Wyeth Corp | Wasserlösliche rapamycin-ester |
| US6399625B1 (en) | 2000-09-27 | 2002-06-04 | Wyeth | 1-oxorapamycins |
| US6399626B1 (en) | 2000-10-02 | 2002-06-04 | Wyeth | Hydroxyesters of 7-desmethylrapamycin |
| US6440991B1 (en) | 2000-10-02 | 2002-08-27 | Wyeth | Ethers of 7-desmethlrapamycin |
| US6923927B2 (en) * | 2000-10-03 | 2005-08-02 | Atrium Medical Corporation | Method for forming expandable polymers having drugs or agents included therewith |
| TWI286074B (en) | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
| TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
| TWI233359B (en) * | 2001-04-06 | 2005-06-01 | Wyeth Corp | Pharmaceutical composition for treating neoplasm |
| ZA200603888B (en) * | 2001-06-01 | 2007-05-30 | Wyeth Corp | Antineoplastic combinations |
| UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
| WO2003018573A1 (en) | 2001-08-22 | 2003-03-06 | Wyeth | Rapamycin 29-enols |
| CA2455311A1 (en) | 2001-08-22 | 2003-03-06 | Wyeth | Rapamycin dialdehydes |
| AU2002352726A1 (en) | 2001-11-15 | 2003-06-10 | Galileo Laboratories, Inc. | Formulations and methods for treatment or amelioration of inflammatory conditions |
| RU2344821C2 (ru) | 2002-07-30 | 2009-01-27 | Уайт | Парентеральные композиции, содержащие гидроксиэфиры рапамицина |
| CN100415233C (zh) * | 2002-09-17 | 2008-09-03 | 惠氏公司 | 口服制剂 |
| AR042938A1 (es) * | 2003-02-06 | 2005-07-06 | Wyeth Corp | Uso del cci-779 en el tratamiento de la fibrosis hepatica |
| UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
| EP1615640B1 (en) * | 2003-04-22 | 2007-01-24 | Wyeth | Antineoplastic combinations |
| US20040236410A1 (en) * | 2003-05-22 | 2004-11-25 | Atrium Medical Corp. | Polymeric body formation |
| US20040236278A1 (en) * | 2003-05-22 | 2004-11-25 | Atrium Medical Corp. | Therapeutic agent delivery |
| US20040236279A1 (en) * | 2003-05-22 | 2004-11-25 | Atrium Medical Corp. | Gaseous therapeutic agent delivery |
| US20040253185A1 (en) * | 2003-06-12 | 2004-12-16 | Atrium Medical Corp. | Medicated ink |
| CA2562962A1 (en) | 2004-04-14 | 2005-11-10 | Wyeth | Process for preparing rapamycin 42-esters and fk-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies |
| EP1768662A2 (en) | 2004-06-24 | 2007-04-04 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
| CA2582374A1 (en) * | 2004-10-04 | 2006-04-20 | Qlt Usa, Inc. | Ocular delivery of polymeric delivery formulations |
| US8313763B2 (en) * | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
| US20070185150A1 (en) | 2005-11-14 | 2007-08-09 | Bedrosian Camille L | Therapeutic methods |
| RU2010104916A (ru) * | 2006-08-16 | 2011-08-20 | Михаил В. Благосклонный (US) | Способ профилактики и лечения возрастных заболеваний |
| CA2660690A1 (en) * | 2006-08-22 | 2008-02-28 | Novartis Ag | Treatment of fibrosing disorders |
| JP6049160B2 (ja) | 2006-09-13 | 2016-12-27 | エリクシアー メディカル コーポレイション | 大環状ラクトン化合物およびその使用方法 |
| US20080175887A1 (en) * | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
| US8425459B2 (en) * | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| EP2092942A1 (en) * | 2006-11-20 | 2009-08-26 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8414526B2 (en) * | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
| US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| JP2011523401A (ja) * | 2008-04-29 | 2011-08-11 | ワイス・エルエルシー | 炎症を治療するための方法 |
| WO2010024898A2 (en) | 2008-08-29 | 2010-03-04 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
| PT2365802T (pt) | 2008-11-11 | 2017-11-14 | Univ Texas | Microcápsulas de rapamicina e utilização para o tratamento de cancro |
| BRPI1010655A2 (pt) | 2009-04-10 | 2019-09-03 | Qi Haiyan | novos agentes antienvelhecimento e métodos para identificá-los |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| US20150290176A1 (en) | 2012-10-12 | 2015-10-15 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors to treat vascular cognitive impairment |
| EP2968281B1 (en) | 2013-03-13 | 2020-08-05 | The Board of Regents of The University of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
| EP3738592B1 (en) | 2013-10-08 | 2022-01-26 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| DK3089737T3 (da) | 2013-12-31 | 2021-12-13 | Rapamycin Holdings Llc | Orale rapamycin-nanopartikelpræparater og anvendelse. |
| KR20160120739A (ko) * | 2014-02-11 | 2016-10-18 | 램 테라퓨틱스, 인코포레이티드 | 림프관평활근종증의 치료를 위한 라파마이신 |
| US10307371B2 (en) | 2014-02-11 | 2019-06-04 | AI Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
| EP3125875B1 (en) | 2014-04-04 | 2023-06-07 | AI Therapeutics, Inc. | An inhalable rapamycin formulation for treating age-related conditions |
| EP3191091B1 (en) | 2014-09-12 | 2020-08-26 | Children's Medical Center Corporation | Dietary emulsion formulations and methods for using the same |
| RU2732908C2 (ru) | 2014-10-07 | 2020-09-24 | ЭйАй ТЕРАПЬЮТИКС, ИНК. | Ингаляционная лекарственная форма рапамицина для лечения легочной гипертензии |
| WO2016066608A1 (en) * | 2014-10-28 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging |
| MA40910A (fr) | 2014-11-07 | 2017-09-12 | Civitas Therapeutics Inc | Poudres de rapamycine pour administration pulmonaire |
| WO2016130645A1 (en) | 2015-02-10 | 2016-08-18 | Lam Therapeutics, Inc. | Rapamycin for the treatment of lymphangioleiomyomatosis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US5023264A (en) * | 1990-07-16 | 1991-06-11 | American Home Products Corporation | Rapamycin oximes |
| WO1992008474A2 (en) * | 1990-11-20 | 1992-05-29 | The National Heart & Lung Institute | Treatment of lung diseases |
-
1991
- 1991-02-22 US US07/659,782 patent/US5080899A/en not_active Expired - Lifetime
-
1992
- 1992-02-10 IL IL10090592A patent/IL100905A/en not_active IP Right Cessation
- 1992-02-19 ZA ZA921211A patent/ZA921211B/xx unknown
- 1992-02-20 NZ NZ241672A patent/NZ241672A/en not_active IP Right Cessation
- 1992-02-20 PT PT100144A patent/PT100144B/pt not_active IP Right Cessation
- 1992-02-21 DE DE69229858T patent/DE69229858T2/de not_active Expired - Fee Related
- 1992-02-21 EP EP92907905A patent/EP0573584B1/en not_active Expired - Lifetime
- 1992-02-21 JP JP4507353A patent/JP2673168B2/ja not_active Expired - Fee Related
- 1992-02-21 DK DK92907905T patent/DK0573584T3/da active
- 1992-02-21 ES ES92907905T patent/ES2135404T3/es not_active Expired - Lifetime
- 1992-02-21 AU AU15356/92A patent/AU662735B2/en not_active Ceased
- 1992-02-21 HU HU9302376A patent/HUT70146A/hu unknown
- 1992-02-21 CA CA002103571A patent/CA2103571C/en not_active Expired - Fee Related
- 1992-02-21 AT AT92907905T patent/ATE183647T1/de not_active IP Right Cessation
- 1992-02-21 SG SG1996004019A patent/SG52403A1/en unknown
- 1992-02-21 IE IE055492A patent/IE920554A1/en not_active IP Right Cessation
- 1992-02-21 KR KR1019930702483A patent/KR100201516B1/ko not_active Expired - Fee Related
- 1992-02-21 WO PCT/US1992/001398 patent/WO1992014476A1/en not_active Ceased
-
1999
- 1999-10-21 LV LVP-99-149A patent/LV12400B/en unknown
- 1999-10-27 GR GR990402771T patent/GR3031681T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0573584B1 (en) | 1999-08-25 |
| GR3031681T3 (en) | 2000-02-29 |
| HK1011284A1 (en) | 1999-07-09 |
| DE69229858T2 (de) | 1999-12-09 |
| KR100201516B1 (ko) | 1999-06-15 |
| LV12400B (en) | 2000-07-20 |
| LV12400A (lv) | 1999-12-20 |
| ES2135404T3 (es) | 1999-11-01 |
| JPH06504790A (ja) | 1994-06-02 |
| SG52403A1 (en) | 1998-09-28 |
| AU1535692A (en) | 1992-09-15 |
| PT100144A (pt) | 1993-08-31 |
| JP2673168B2 (ja) | 1997-11-05 |
| WO1992014476A1 (en) | 1992-09-03 |
| ZA921211B (en) | 1993-08-19 |
| EP0573584A4 (es) | 1994-02-16 |
| HUT70146A (en) | 1995-09-28 |
| IL100905A0 (en) | 1992-11-15 |
| KR930703000A (ko) | 1993-11-29 |
| IE920554A1 (en) | 1992-08-26 |
| AU662735B2 (en) | 1995-09-14 |
| US5080899A (en) | 1992-01-14 |
| CA2103571A1 (en) | 1992-08-23 |
| DK0573584T3 (da) | 1999-12-13 |
| NZ241672A (en) | 1997-06-24 |
| CA2103571C (en) | 2003-04-29 |
| ATE183647T1 (de) | 1999-09-15 |
| DE69229858D1 (de) | 1999-09-30 |
| EP0573584A1 (en) | 1993-12-15 |
| PT100144B (pt) | 1999-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU662735B2 (en) | Method of treating pulmonary inflammation | |
| JP2810599B2 (ja) | 免疫炎症性疾患の治療用医薬組成物 | |
| US5683675A (en) | Method of treating retained pulmonary secretions | |
| EP1628682B1 (en) | Composition comprising a pde4 inhibitor and a pde5 inhibitor for the treatment of copd | |
| IE920556A1 (en) | Method for treating Systemic Lupus Erythematosus | |
| US20040147544A1 (en) | Pde4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases | |
| AU2002363443A1 (en) | New uses for anti-malarial therapeutic agents | |
| EP0416925A2 (en) | Use of 4-hydroxy-alpha 1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol or its salts in the treatment of allergy and inflammation | |
| WO1992011016A1 (en) | Pharmaceutical composition containing uridine 5'-triphosphate for the treatment of cystic fibrosis | |
| Minneman et al. | Cholera toxin induces pineal enzymes in culture | |
| CA2270373A1 (en) | Synergistic composition comprising rapamycin and calcitriol | |
| HK1011284B (en) | Method of treating pulmonary inflammation | |
| JPH10502058A (ja) | アリール、アルキル、アルケニルおよびアルキニルマクロライド | |
| MXPA04005506A (es) | Composiciones farmaceuticas de adenosina a2a y agonistas del receptor beta-2-adrenergico. | |
| EP0979650A1 (en) | Antiviral agents | |
| WO2003047628A1 (en) | Combination of an adenosine a2a receptor agonist and an adrenergic beta-2 receptor agonist | |
| WO1999030695A1 (en) | Substituted amidino compounds in the treatment of chronic obstructive pulmonary disease | |
| WO2001091760A1 (en) | New use | |
| Ruffie et al. | Modulation of the bronchial inflammation in sensitized guinea-pigs by FK506, nedocromil sodium and dexamethasone | |
| KR20110089159A (ko) | 환상 뎁시펩티드 화합물 및 그의 용도 | |
| US20040044016A1 (en) | Antiviral agents | |
| Kay | Resistant asthma. | |
| JPH04226916A (ja) | ベンゾシクロヘプタチオフェンカルボン酸誘導体の新規医薬用途 | |
| HK1162140A (en) | 5-ht4 inhibitors for treating airway diseases, in particular asthma | |
| HU211559A9 (hu) | Immunszupresszáns hatású imidazolidil-makrolidok Az átmeneti oltalom az 1-13. igénypontokra vonatkozik. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| HCA | Change of name of proprietor(s) after amalgamation | ||
| MM9K | Patent not in force due to non-payment of renewal fees |